KYNU and lung adenocarcinoma: Recently, we reported an unrecognized role of NRF2 activation through loss-of-function KEAP1 mutations in upregulating the tryptophan-metabolizing enzyme kynureninase (KYNU) in lung adenocarcinoma (LUAD) [3].